Effectiveness of Botulinum Toxin for Oncologic Pain

Authors

Abstract

Introduction: The use of botulinum toxin for medical purposes has expanded nowadays through the extensive study of its complex structure and mechanism of action, highlighting its ability to inhibit the release of acetylcholine, and its impact on the chemical signaling cascade involved in different models of pain.

Objective: To evaluate the association of the use of botulinum toxin A with the reduction of pain in oncologic patients at Instituto Nacional de Cancerología, México.

Methodology: A retrospective, observational, descriptive, and cross-sectional study was performed. Data were obtained from patients attended during the period from January 1, 2022 to September 30, 2023 in whom botulinum toxin was applied as an adjuvant for pain management.

Results: Thirty-two patients who met the inclusion criteria were included. After the application of botulinum toxin there was a statistically significant reduction in pain, as measured by the Numeric Pain Rating Scale and Verbal Rating Scale. The degree of satisfaction after the application of botulinum toxin was measured by a Likert-type scale, and 68% satisfaction was found in the patients who underwent the onotoxin treatment.

Conclusions: The use of botulinum toxin proved to be an effective and safe therapy, complementary to the multimodal approach for the treatment of different pain patterns in oncologic patients. It can be considered as a pharmacological option for use in this group of patients.

Keywords: Oncologic pain, Pain management, Botulinum toxin

Keywords:

ONCOLOGIC PAIN, PAIN MANAGEMENT, BOTULINUM TOXIN

DOI

https://doi.org/10.22270/jddt.v14i2.6414

Author Biographies

Daniela Hernández-Rodríguez, Pain Management, Instituto Nacional de Cancerología, México

Pain Management, Instituto Nacional de Cancerología, México

María del Rocío Guillén-Núñez, Interventional Pain Management and Palliative Care, Instituto Nacional de Cancerología, México;

Interventional Pain Management and Palliative Care, Instituto Nacional de Cancerología, México;

Angel Manuel Juárez-Lemus, Interventional Pain Management and Palliative Care, Instituto Nacional de Cancerología, México;

Interventional Pain Management and Palliative Care, Instituto Nacional de Cancerología, México;

Ricardo Plancarte-Sánchez, Interventional Pain Management and Palliative Care, Pain Clinic Head of Department, Instituto Nacional de Cancerología, México;

Interventional Pain Management and Palliative Care, Pain Clinic Head of Department, Instituto Nacional de Cancerología, México;

Blanca Betsabé Aguilera-Elizalde, Pain Management, Instituto Nacional de Cancerología, México;

Pain Management, Instituto Nacional de Cancerología, México;

Oliver Humberto González-Vega, Pain Management, Instituto Nacional de Cancerología, México;

Pain Management, Instituto Nacional de Cancerología, México;

References

Erbguth FJ. From poison to remedy: The chequered history of botulinum toxin. Journal of Neural Transmission. 2007;115(4):559-65. https://doi.org/10.1007/s00702-007-0728-2 PMid:17458494

Flynn TC. Advances in the use of botulinum neurotoxins in facial esthetics. Journal of Cosmetic Dermatology. 2012;11(1):42-50. https://doi.org/10.1111/j.1473-2165.2011.00593.x PMid:22360334

Segura-Aguilar, J.; Tizabi, Y. Botulinum Neurotoxin, an Example of Successful Translational Research. Clin. Pharmacol Transl Med. 2018;2:125.

Aoki KR, Guyer B. Botulinum toxin type A and other botulinum toxin serotypes: A comparative review of biochemical and pharmacological actions. European Journal of Neurology. 2001;8(s5):21-9. https://doi.org/10.1046/j.1468-1331.2001.00035.x PMid:11851731

Dolly JO, Aoki KR. The structure and mode of action of different botulinum toxins. European Journal of Neurology. 2006;13(s4):1-9. https://doi.org/10.1111/j.1468-1331.2006.01648.x PMid:17112344

Yao G, Zhang S, Mahrhold S, Lam K, Stern D, Bagramyan K, et al. N-linked glycosylation of SV2 is required for binding and uptake of botulinum neurotoxin a. Nature Structural & Molecular Biology. 2016;23(7):656-62. https://doi.org/10.1038/nsmb.3245 PMid:27294781 PMCid:PMC5033645

Jabbari B. Basics of structure and mechanisms of function of botulinum toxin - how does it work? Botulinum Toxin Treatment. 2018;11-7. https://doi.org/10.1007/978-3-319-99945-6_2

Burstein R, Blumenfeld AM, Silberstein SD, Manack Adams A, Brin MF. Mechanism of action of onabotulinumtoxin in chronic migraine: A narrative review. Headache: The Journal of Head and Face Pain. 2020;60(7):1259-72. https://doi.org/10.1111/head.13849 PMid:32602955 PMCid:PMC7496564

Santos-Lasaosa S, Cuadrado ML, Gago-Veiga AB, Guerrero-Peral AL, Irimia P, Láinez JM, et al. Evidencia y experiencia del uso de onabotulinumtoxina en neuralgia del trigémino y cefaleas primarias distintas de la migraña crónica. Neurología. 2020;35(8):568-78. https://doi.org/10.1016/j.nrl.2017.09.003 PMid:29169811

Scott AB. Botulinum toxin injection into extraocular muscles as an alternative to strabismus surgery. Ophthalmology. 1980;87(10):1044-9. https://doi.org/10.1016/S0161-6420(80)35127-0 PMid:7243198

Ferrari A. Pharmacological differences and clinical implications of various botulinum toxin preparations: A critical appraisal. Functional Neurology. 2018;33(1):7. https://doi.org/10.11138/FNeur/2018.33.1.007 PMid:29633692 PMCid:PMC5901944

Simpson DM, Hallett M, Ashman EJ, Comella CL, Green MW, Gronseth GS, et al. Practice guideline update summary: Botulinum neurotoxin for the treatment of blepharospasm, cervical dystonia, adult spasticity, and headache. Neurology. 2016;86(19):1818-26. https://doi.org/10.1212/WNL.0000000000002560 PMid:27164716 PMCid:PMC4862245

Moore C, Hulsopple C, Boyce B. Utilization of botulinum toxin for musculoskeletal disorders. Current Sports Medicine Reports. 2020;19(6):217-22. https://doi.org/10.1249/JSR.0000000000000720 PMid:32516192

Ezzati K, Prevalence of Cervical Myofascial Pain Syndrome and its Correlation with the Severity of Pain and Disability in Patients with Chronic Non-specific Neck Pain. The archives of bone and joint surgery. 2021;230:234 doi:10.22038/abjs.2020.48697.2415

Ginszt M, Szkutnik J, Zieliński G, Bakalczuk M, Stodółkiewicz M, Litko-Rola M, et al. Cervical myofascial pain is associated with an imbalance of masticatory muscle activity. International Journal of Environmental Research and Public Health.2022;19(3):1577. https://doi.org/10.3390/ijerph19031577 PMid:35162600 PMCid:PMC8834744

Mayoral del Moral O, Torres Lacomba M, Russell IJ, Sánchez Méndez Ó, Sánchez Sánchez B. Validity and reliability of clinical examination in the diagnosis of myofascial pain syndrome and myofascial trigger points in upper quarter muscles. Pain Medicine. 2017;19(10):2039-50. https://doi.org/10.1093/pm/pnx315 PMid:29253210

Yao G, Zhang S, Mahrhold S, Lam K, Stern D, Bagramyan K, et al. N-linked glycosylation of SV2 is required for binding and uptake of botulinum neurotoxin a. Nature Structural & Molecular Biology. 2016;23(7):65662. https://doi.org/10.1038/nsmb.3245 PMid:27294781 PMCid:PMC5033645

Latorre G, González-García N, García-Ull J, González-Oria C, Porta-Etessam J, Molina FJ, et al. Diagnóstico y tratamiento de la neuralgia del trigémino: Documento de Consenso del Grupo de Estudio de cefaleas de la Sociedad Española de Neurología. Neurología. 2023;38. https://doi.org/10.1016/j.nrl.2021.09.015

Zhang YK, Lian Y, Ma Y, Chen Y, He C, Xie N, et al. Two dosis of botulinum toxin type A for the treatment of trigeminal neuralgia: Observation of therapeutic effect from a randomized, double-blind, placebo-controlled trial. J Headache Pain. 2014. https://doi.org/10.1186/1129-2377-15-65 PMid:25263254 PMCid:PMC4194456

Grenda, T, Botulinum toxin in cancer therapy-current perspectives and limitations. Applied microbiology and biotechnology, 2020;485:495 https://doi.org/10.1007/s00253-021-11741-w PMid:34951660 PMCid:PMC8763801

Lippi L, de Sire A, Folli A, D'Abrosca F, Grana E, Baricich, et al. Multidimensional Effectiveness of Botulinum Toxin in neuropathic pain: A systematic review of randomized clinical trials. Toxins, 2022;14(5):3088. https://doi.org/10.3390/toxins14050308 PMid:35622555 PMCid:PMC9145715

Zhang H, Lian Y, Ma Y, Chen Y, He C, Xie N, Wu C. Two doses of botulinum toxin type A for the treatment of trigeminal neuralgia: observation of therapeutic effect from a randomized, double-blind, placebo-controlled trial. The Journal of Headache and Pain. 2014;15(1):65. https://doi.org/10.1186/1129-2377-15-65 PMid:25263254 PMCid:PMC4194456

Published

15-02-2024
Statistics
Abstract Display: 175
PDF Downloads: 168
PDF Downloads: 15

How to Cite

1.
Hernández-Rodríguez D, Guillén-Núñez M del R, Juárez-Lemus AM, Plancarte-Sánchez R, Aguilera-Elizalde BB, González-Vega OH. Effectiveness of Botulinum Toxin for Oncologic Pain. J. Drug Delivery Ther. [Internet]. 2024 Feb. 15 [cited 2025 Feb. 19];14(2):7-13. Available from: https://jddtonline.info/index.php/jddt/article/view/6414

How to Cite

1.
Hernández-Rodríguez D, Guillén-Núñez M del R, Juárez-Lemus AM, Plancarte-Sánchez R, Aguilera-Elizalde BB, González-Vega OH. Effectiveness of Botulinum Toxin for Oncologic Pain. J. Drug Delivery Ther. [Internet]. 2024 Feb. 15 [cited 2025 Feb. 19];14(2):7-13. Available from: https://jddtonline.info/index.php/jddt/article/view/6414

Most read articles by the same author(s)